During the progression from premalignant lesion to invasive carcinoma, KRAS mutations are the initial events where > 90% of PanIN lesions harbor these mutations, followed by the accumulation of tumor suppressive genes such as p16, Smad4, and TP53 [9, 18]. This evidence concerns the gene TP53 and invasive carcinoma.